SEC Tracker
Get the app
TKNO · XBRL financial data

Alpha Teknova financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TKNO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers8,1697,867*9,2909,6149,5769,265*9,79510,28710,4549,984*11,07712,185
Cost of goods and services sold6,6976,532*7,0816,8109,4867,137*6,7886,3037,2486,740*7,2937,300
Gross profit1,4721,335*2,2092,804902,128*3,0073,9843,2063,244*3,7844,885
Research and development1,3971,311*860678627594*552581542522*609554
General and administrative6,1386,024*7,3815,4834,9685,318*5,4924,9294,6475,250*5,0584,812
Total operating expenses10,23412,193*10,1957,9047,5227,756*7,9717,3707,2237,853*8,0827,775
Operating income (loss)(8,762)(10,858)*(7,986)(5,100)(7,432)(5,628)*(4,964)(3,386)(4,017)(4,609)*(4,298)(2,890)
Other income (expense)233(275)*0000*—(165)———(250)
Income tax expense (benefit)9(304)*(34)(8)(8)(38)*221979(62)*4730
Net income (loss)(10,153)(10,656)*(8,097)(5,364)(7,565)(5,719)*(4,645)(3,570)(4,286)(4,758)*(4,555)(3,170)
Earnings per share, basic USD per share(0.34)—(0.20)(0.13)(0.15)(0.11)*(0.09)(0.07)(0.08)(0.09)*(0.08)(0.06)
Earnings per share, diluted USD per share(0.34)—(0.20)(0.13)(0.15)(0.11)*(0.09)(0.07)(0.08)(0.09)*(0.08)(0.06)
Weighted average shares, basic thousands of shares29,957—40,80540,85451,82153,375*53,42253,44953,51753,543*53,60653,635
Weighted average shares, diluted thousands of shares29,957—40,80540,85451,82153,375*53,42253,44953,51753,543*53,60653,635

Balance sheet

CSV

Fiscal quarters (TKNO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents32,07928,48421,59618,5966,1453,7083,3773,2763,2045,9124,3066,004
Short-term investments—0——25,54626,68822,89620,72418,91215,42613,47811,432
Accounts receivable5,1603,9484,5604,5974,6054,3125,6165,1405,1354,6185,6725,408
Inventory11,46811,59411,20710,9877,6746,8016,5737,6106,9147,0546,8746,911
Prepaid and other current assets2,3711,6341,4601,1041,9601,2671,2711,3072,3981,5011,3441,069
Total current assets51,07845,66038,82335,28445,93042,77639,73338,05736,56334,51131,67430,824
Property and equipment, net51,57950,36448,90747,77746,71545,75344,72843,60542,62341,73340,52439,311
Right-of-use asset17,08016,47217,40016,98116,55815,76715,40914,96014,89414,11213,60813,247
Total assets138,385128,587120,817115,353124,099118,769113,993110,487107,625103,58498,65795,878
Accounts payable1,4221,4931,5431,0239758251,5551,2041,0841,3781,6181,438
Accrued liabilities5,1475,5793,5743,4984,3734,5413,6403,3883,9664,2833,3633,476
Current portion of long-term debt—0—1,0112,5284,0450000——
Total current liabilities8,3398,8757,0397,4139,71911,2117,0456,4786,9367,5376,8966,872
Long-term debt13,16813,25113,17812,27110,857———————
Lease liability, non-current15,87315,40416,26015,81215,35814,88414,50614,05214,01713,27012,74212,232
Total liabilities38,73338,55137,43936,42536,83136,37535,38834,43034,97534,80933,73333,278
Accumulated deficit(81,130)(91,786)(99,883)(105,247)(112,812)(118,531)(123,176)(126,746)(131,032)(135,790)(140,345)(143,515)
Total stockholders' equity99,65290,03683,37878,92887,26882,39478,60576,05772,65068,77564,92462,600
Total liabilities and equity138,385128,587120,817115,353124,099118,769113,993110,487107,625103,58498,65795,878
Common shares outstanding (cover page) thousands of shares40,72840,82340,82353,30353,30853,43753,44153,51553,52953,58853,61453,688

Cash flows

CSV

Fiscal quarters (TKNO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(10,153)(10,656)*(8,097)(5,364)(7,565)(5,719)*(4,645)(3,570)(4,286)(4,758)*(4,555)(3,170)
Stock-based compensation1,035*1,022*1,307833*760*766*852950*850*777*695622*
Depreciation and amortization1,622*1,611*1,6361,626*1,671*1,645*1,5801,590*1,591*1,581*1,5761,593*
Net cash from operating activities(4,382)*(2,892)*(6,558)(2,838)*(2,059)*(936)*(4,103)(2,101)*(1,980)*(462)*(3,359)(471)*
Purchases of property and equipment972*312*112115*331*567*206207*387*348*221125*
Net cash from investing activities(972)*(115)*13(115)*(25,759)*(1,414)*3,8242,028*1,640*3,207*1,8411,945*
Proceeds from issuing common stock22,915*(412)*(37)0*15,141*0*———0*——
Proceeds from long-term debt0*0*——————————
Repayments of long-term debt—0*———0*——————
Net cash from financing activities13,625*(621)*(343)(47)*15,367*(87)*(52)(28)*268*(37)*(88)224*
Net change in cash8,271*(3,628)*(6,888)(3,000)*(12,451)*(2,437)*(331)(101)*(72)*2,708*(1,606)1,698*

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Alpha Teknova6,00412,185(471)*53.7M37.0 quarters 10-QJun 30, 2026
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026
Fitlife Brands1,089not reported3,635*9.4M— 10-QJun 30, 2026
Immucell8,8607,1863,019*9.1M— 10-QJun 30, 2026
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026
Mersana Therapeutics56,39111,009(3,192)*5.0M17.7 quarters 10-QSep 30, 2025
Sutro Biopharma54,3359,839(38,290)*16.6M4.3 quarters 10-QJun 30, 2026
PDS Biotechnology5,596not reported(2,793)*56.0M2.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.